Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HIV/AIDS NDAs For Fixed-Dose Combination Will Be Exempt From User Fees

This article was originally published in The Pink Sheet Daily

Executive Summary

Expedited FDA review process for combination antiretroviral drugs announced at World Health Organization meeting. Generic versions of patented medicines would receive a “tentative” approval and be eligible for use in the Administration’s $15 bil. assistance program.

You may also be interested in...



Atripla Approved As First Once-Daily, Single-Tablet HIV Therapy

The Bristol/Gilead combination product will launch within seven business days.

Atripla Approved As First Once-Daily, Single-Tablet HIV Therapy

The Bristol/Gilead combination product will launch within seven business days.

U.S. Patents Could Limit President's AIDS Drug Assistance Plan, GAO Says

The U.S. Global AIDS Coordinator's Office suggests it will use its authority to purchase an FDA-approved generic antiretroviral product for which permission could not be obtained from the patent holder. FDA grants tentative approval to a South African firm for a generic co-packaged version of Combivir and Viramune.

Related Content

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel